# Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)

> **NCT04285346** · PHASE2 · COMPLETED · sponsor: **Marinus Pharmaceuticals** · enrollment: 23 (actual)

## Conditions studied

- Tuberous Sclerosis

## Interventions

- **DRUG:** Ganaxolone

## Key facts

- **NCT ID:** NCT04285346
- **Lead sponsor:** Marinus Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-08
- **Primary completion:** 2021-06-25
- **Final completion:** 2022-08-30
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04285346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04285346, "Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04285346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*